HAE - KalVista jumps as rare disease therapy hits main goal in Phase 3 trial
2024-02-13 07:17:05 ET
More on KalVista Pharmaceticals
- KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
- Seeking Alpha’s Quant Rating on KalVista Pharmaceticals
- Historical earnings data for KalVista Pharmaceticals
- Financial information for KalVista Pharmaceticals